Loading
A phase 2 trial of Inavolisib, Ribociclib and Giredestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer is a phase 2 interventional study registered as NCT07054190 by Hoffmann-La Roche, with 120 participants planned, started 2025-09-09 and due to reach its primary completion in 2027-07-31. Interventions recorded: Inavolisib, Ribociclib, Letrozole and Giredestrant.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Ribociclib and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Giredestrant, Inavolisib, Flatiron Health (Roche), Ribociclib and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/